---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056949"
form_type: "8-K"
ticker: null
cik: "0001888012"
company_name: "HilleVax, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:12:31.712591+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# HilleVax Q1 net loss widens to $46.8M; cash at $272.7M; NEST-IN1 data due mid-2024

## Summary
- Net loss $46.8M vs $26.9M YoY; R&D expenses $26.0M (up from $23.2M); G&A $8.5M (up from $5.8M).
- Cash, equivalents and marketable securities $272.7M as of March 31, 2024, down from $303.5M at Dec 31, 2023.
- Topline safety and efficacy data from NEST-IN1 Phase 2b trial of HIL-214 in infants expected in mid-2024.
- Appointed Sean McLoughlin as COO during Q1 2024.

## SEC filing metadata
- accession: 0000950170-24-056949
- form_type: 8-K
- cik: 0001888012
- company_name: HilleVax, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/0000950170-24-056949-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/hlvx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056949
- JSON: https://secwatch.observer/filing/0000950170-24-056949.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056949.txt

## Key facts
- Earnings Releases
  HilleVax, Inc. reported the quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023.
  - Period: the quarter ended March 31, 2024
  - Net income: Net loss for the first quarter 2024 was $46.8 million, compared to $26.9 million for the first quarter 2023
  - Result: reported results
  source text: HilleVax, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888012/000095017024056949/0000950170-24-056949-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.